Valuation: Aclarion, Inc.

Market Cap 7.02M 6.14M 5.67M 5.3M 9.97M 663M 10.2M 68.26M 26.35M 327M 26.35M 25.77M 1.14B P/E 2026 *
-0.63x
P/E 2027 * -0.52x
Enterprise Value 7.02M 6.14M 5.67M 5.3M 9.97M 663M 10.2M 68.26M 26.35M 327M 26.35M 25.77M 1.14B EV / Sales 2026 *
52x
EV / Sales 2027 * 27.3x
Free-Float
73.8%
Yield 2026 *
-
Yield 2027 * -
1 day+0.35%
1 week-5.92%
Current month-12.80%
1 month-12.80%
3 months-7.14%
6 months-42.11%
Current year-37.83%
1 week 2.62
Extreme 2.62
3.05
1 month 2.62
Extreme 2.62
3.61
Current year 2.34
Extreme 2.3401
9.36
1 year 2.34
Extreme 2.3401
12.03
3 years 2.34
Extreme 2.3401
112,881.52
5 years 2.34
Extreme 2.3401
586,115.57
10 years 2.34
Extreme 2.3401
586,115.57
Manager TitleAgeSince
Chief Executive Officer 60 2021-09-14
Director of Finance/CFO 60 2025-09-01
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member 69 2015-12-31
Chairman 62 2022-04-20
Director/Board Member 60 2021-09-14
Date Insider Type Main position Quantity % Market Cap.
06-10Free

Director

20,000 0.8123%
06-10Free

Chief Financial Officer

50,000 2.0307%
06-10Free

Director

20,000 0.8123%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%-5.92%-61.99%-100.00% 7.02M
+0.94%+7.83%-4.50%+3.17% 46.2B
+2.17%+11.77%+403.75%+606.83% 38.71B
-0.08%+13.80%+21.18%-13.75% 31.9B
+2.46%+5.54%+18.51%+60.63% 31.12B
+8.02%+5.23%+17.67%+35.36% 23.77B
-0.09%+14.07% - - 16.2B
-0.33%+15.13%+67.14%+123.28% 15.05B
-1.13%+7.40%+12.81%+20.67% 13.74B
-0.64%+6.02%+103.63%+95.71% 13.42B
Average +1.10%+8.68%+64.24%+92.43% 23.01B
Weighted average by Cap. +1.44%+10.07%+91.95%+137.19%

Financials

2026 *2027 *
Net sales 135K 118K 109K 102K 192K 12.76M 196K 1.31M 507K 6.3M 507K 496K 21.86M 257K 225K 208K 194K 365K 24.3M 373K 2.5M 965K 11.99M 965K 944K 41.62M
Net income -10.71M -9.38M -8.66M -8.08M -15.22M -1.01B -15.56M -104M -40.21M -499M -40.21M -39.33M -1.73B -13.47M -11.79M -10.89M -10.17M -19.14M -1.27B -19.57M -131M -50.57M -628M -50.57M -49.46M -2.18B
Net Debt - -
Logo Aclarion, Inc.
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Employees
11
Date Price Change Volume
26-06-29 US$2.860 +0.35% 26,106
26-06-26 US$2.850 +5.17% 40,793
26-06-25 US$2.710 -1.09% 83,764
26-06-24 US$2.740 -5.19% 151,482
26-06-23 US$2.890 -4.93% 57,957
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.850USD
Average target price
7.500USD
Spread / Average Target
+163.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACON Stock